Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.30 +0.11 (+9.24%)
At close: Oct 1, 2026 · 4:00 PM EDT

Chemomab Therapeutics (CMMB) Liabilities and Shareholders Equity (2017 - 2026)

Updated

Chemomab Therapeutics' Liabilities and Shareholders Equity was $10.24 million in Q2 2026, down 8.0% from $11.13 million a year earlier and down 13.3% from the prior quarter.

Analysis

Chemomab Therapeutics (CMMB) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Chemomab Therapeutics came in at $13.81 million, down 18.6% from FY2024.

  • Liabilities and Shareholders Equity has now declined for four consecutive years, though with a five-year compound annual growth rate of 2.1% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $16.96 million in FY2024 (-23.4%), $22.15 million in FY2023 (-48.6%), $43.06 million in FY2022 (-33.1%) and $64.35 million in FY2021 (+415.8%).
  • The Q2 2026 figure marks the lowest quarterly Liabilities and Shareholders Equity since Q3 2020.
  • Compared with a year earlier, Liabilities and Shareholders Equity has declined for 17 straight quarters, with an average decline of 20.2% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q3 2021 (growth of 777.1%); the worst was Q3 2023 (a decline of 53.4%).
  • Per Business Quant data, CMMB's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $11.81 million (Q1 2026), $13.81 million (Q4 2025) and $12.37 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Chemomab Therapeutics 8.56 Mn 8.56 Mn - 10.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.24 Mn
Mar 31, 2026 11.81 Mn
Dec 31, 2025 13.81 Mn
Sep 30, 2025 12.37 Mn
Jun 30, 2025 11.13 Mn
Mar 31, 2025 12.82 Mn
Dec 31, 2024 16.96 Mn
Sep 30, 2024 20.90 Mn
Jun 30, 2024 14.54 Mn
Mar 31, 2024 18.01 Mn
Dec 31, 2023 22.15 Mn
Sep 30, 2023 23.42 Mn
Jun 30, 2023 28.85 Mn
Mar 31, 2023 35.01 Mn
Dec 31, 2022 43.06 Mn
Sep 30, 2022 50.22 Mn
Jun 30, 2022 56.38 Mn
Mar 31, 2022 60.96 Mn
Dec 31, 2021 64.35 Mn
Sep 30, 2021 67.44 Mn
API Access

Chemomab Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=CMMB&period=max&api_key=YOUR_API_KEY